-
Does ChemoSNiP examine the cause of mutation?
The ChemoSNiP test provides information about DNA mutations that can affect how humans develop cancer or respond to anti-cancer drugs and treatments.
-
Can Oncotrace differentiate between benign and malignant tumours?
Yes. The Oncotrace test provides information about the presence of circulating tumour cells, their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.
-
Can Immune-Frame tell if a patient’s immune system is suppressed as a result of cancer or if a suppressed immune system caused the cancer?
The Immune-Frame test focuses on the status of a patient’s immune system, based on their cellular markers and the level of cytokine proteins in the test sample.
-
How often should patients carry out a follow-up test?
This should be determined by your treatment plan.
-
How often will I need follow-up support tools?
Every three months for the first year, then every six months.
-
Do you have testimonials from doctors who have used RGCC tests?
Yes, we would be happy to share details of doctors and clinics with whom we regularly collaborate. Please contact us for more information.
